GPS Wealth Strategies Group’s Viking Therapeutics VKTX Stock Holding History

GPS Wealth Strategies Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$28.2K	Sell	803 -2,485	-76%	-$88K	0.02%	275
2025 Q3	$86.4K	Buy	3,288 +450	+16%	+$13.4K	0.01%	535
2025 Q2	$75.2K	Buy	2,838 +1,844	+186%	+$48.5K	0.01%	540
2025 Q1	$24K	Sell	994 -455	-31%	-$14.4K	﹤0.01%	786
2024 Q4	$58.3K	Sell	1,449 -650	-31%	-$37.1K	0.01%	549
2024 Q3	$133K	Buy	2,099 +535	+34%	+$31.4K	0.02%	379
2024 Q2	$82.9K	Buy	1,564 +1,229	+367%	+$80.6K	0.01%	428
2024 Q1	$27.5K	Buy	+335	New	+$14.9K	﹤0.01%	645

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPS Wealth Strategies Group's VKTX Position: Q4 2025 in Review

GPS Wealth Strategies Group reduced its Viking Therapeutics (VKTX) stake by 76% in Q4 2025, selling an estimated $88K and leaving 803 shares worth $28.2K. The position accounts for 0.02% of the portfolio, ranked #275.

GPS Wealth Strategies Group first reported a position in VKTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $133K in Q3 2024. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

GPS Wealth Strategies Group held 803 shares of Viking Therapeutics worth $28.2K as of Q4 2025.
GPS Wealth Strategies Group sold 2,485 Viking Therapeutics shares in Q4 2025, an estimated $88K.
Viking Therapeutics made up 0.02% of GPS Wealth Strategies Group's portfolio in Q4 2025, its #275 holding.
GPS Wealth Strategies Group first reported a position in Viking Therapeutics in Q1 2024 and has held it in 8 quarters since.
GPS Wealth Strategies Group's Viking Therapeutics position peaked at $133K in Q3 2024.
426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on GPS Wealth Strategies Group's 13F filing for Q4 2025, filed 6 Feb 2026.